Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3 OCT 19 BEILSTEIN updated with new compounds
NEWS 4 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 5 NOV 19 WPIX enhanced with XML display format
NEWS 6 NOV 30 ICSD reloaded with enhancements
NEWS 7 DEC 04 LINPADOCDB now available on STN
NEWS 8 DEC 14 BEILSTEIN pricing structure to change
NEWS 9 DEC 17 USPATOLD added to additional database clusters
NEWS 10 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 11 DEC 17 DGENE now includes more than 10 million sequences
NEWS 12 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14 DEC 17 CA/CAplus enhanced with new custom IPC display formats
NEWS 15 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16 JAN 02 STN pricing information for 2008 now available
NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19 JAN 28 MARPAT searching enhanced
NEWS 20 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23 FEB 08 STN Express, Version 8.3, now available
NEWS 24 FEB 20 PCI now available as a replacement to DPCI

NEWS 25 FEB 25 IFIREF reloaded with enhancements
NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 27 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:47:24 ON 11 MAR 2008

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:47:51 ON 11 MAR 2008

FILE COVERS 1907 - 11 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 10 Mar 2008 (20080310/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 1-8D or IFITM2
9534696 1
1443 8D
37 1-8D
(1(W)8D)
39 IFITM2
L1 76 1-8D OR IFITM2

=> s L1 and (colon and (cancer or carcinoma or tumor or tumour or neoplasia or malignancy)
UNMATCHED LEFT PARENTHESIS 'AND (COLON'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s L1 and (colon and (cancer or carcinoma or tumor or tumour or neoplasia or malignancy))
66065 COLON
778 COLONS
1710 COLA
87 COLAS
67949 COLON
(COLON OR COLONS OR COLA OR COLAS)
350758 CANCER
51562 CANCERS
363777 CANCER
(CANCER OR CANCERS)
177176 CARCINOMA
34212 CARCINOMAS
171 CARCINOMATA
185424 CARCINOMA
(CARCINOMA OR CARCINOMAS OR CARCINOMATA)
443314 TUMOR
166728 TUMORS
494863 TUMOR
(TUMOR OR TUMORS)
3645 TUMOUR
1377 TUMOURS

4935 TUMOUR
(TUMOUR OR TUMOURS)
15501 NEOPLASIA
1538 NEOPLASIAS
16662 NEOPLASIA
(NEOPLASIA OR NEOPLASIAS)
17751 MALIGNANCY
18136 MALIGNANCIES
33131 MALIGNANCY
(MALIGNANCY OR MALIGNANCIES)
L2 8 L1 AND (COLON AND (CANCER OR CARCINOMA OR TUMOR OR TUMOUR OR
NEOPLASIA OR MALIGNANCY))

=> duplicate remove L2
PROCESSING COMPLETED FOR L2
L3 8 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> d L2 bib abs 1-8

L2 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1408247 CAPLUS
TI 1-8 interferon inducible gene family': putative colon carcinoma-associated antigens
AU Tirosh, B.; Daniel-Carmi, V.; Carmon, L.; Paz, A.; Lugassy, G.; Vadai, E.; Machlenkin, A.; Bar-Haim, E.; Do, M.-S.; Ahn, I. S.; Fridkin, M.; Tzehoval, E.; Eisenbach, L.
CS Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
SO British Journal of Cancer (2007), 97(12), 1655-1663
CODEN: BJCAAI; ISSN: 0007-0920
PB Nature Publishing Group
DT Journal
LA English
AB Db-/-x.beta.2 microglobulin (.beta.2m) null mice transgenic for a chimeric HLA-A2.1/Db-.beta.2m single chain (HHD mice) are an effective biol. tool to evaluate the antitumor cytotoxic T-lymphocyte response of known major histocompatibility-restricted peptide tumor-assocd. antigens, and to screen for putative unknown novel peptides. We utilized HHD lymphocytes to identify immunodominant epitopes of colon carcinoma overexpressed genes. We screened with HHD-derived lymphocytes over 500 HLA-A2.1-restricted peptides derived from colon carcinoma overexpressed genes. This procedure culminated in the identification of seven immunogenic peptides, three of these were derived from the human 1-8D gene from interferon inducible gene' (1-8D). The 1-

8D gene was shown to be overexpressed in fresh tumor samples. The three 1-8D peptides were both antigenic and immunogenic in the HHD mice. The peptides induce cytotoxic T lymphocytes that were able to kill a colon carcinoma cell line HCT/HHD, in vitro and retard its growth in vivo. One of the peptides shared by all the 1-8 gene family primed efficiently normal human cytotoxic T lymphocyte precursors. These results highlight the 1 -8D gene and its homologues as putative immunodominant tumor-assocd. antigens of colon carcinoma.
British Journal of Cancer (2007) 97, 1655-1663.
doi:10.1038/sj.bjc.6604061 www.bjcancer.com Published online 11 Dec. 2007.

L2 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:147678 CAPLUS
DN 144:206999
TI Fragilis and Stella genes and proteins expressed in primordial germ cells and their uses as cell markers and for diagnosis and treatment of disease
IN Saitou, Mitinori; Surani, Azim
PA UK
SO U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of Appl. No. PCT/GB03/03093.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006035326	A1	20060216	US 2005-38676	20050118
WO 2004007723	A2	20040122	WO 2003-GB3093	20030717
WO 2004007723	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2002-16727	A	20020717	
US 2002-397310P	P	20020719	
WO 2003-GB3093	A2	20030717	

AB The present invention relates to two primordial germ cell-specific expressed genes, Fragilis and Stella. The sequences and uses of human Stella and Fragilis are disclosed herein, as are several mouse sequences related to Fragilis. The present invention relates to the use of Stella

and Fragilis as markers for primordial germ cells and can be used to identify such cells. Addnl., the present invention relates to the use of Stella and Fragilis for the diagnosis, treatment, and/or prevention of disease.

L2 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:523621 CAPLUS
DN 143:54416
TI DNA microarray for identifying genes regulated by basal transcription factors and biomarkers for treating diseases through regulation of hepatocyte nuclear factors
IN Odom, Duncan T.; Young, Richard A.
PA Whitehead Institute for Biomedical Research, USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005054461	A2	20050616	WO 2004-US39805	20041123
WO 2005054461	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005239106	A1	20051027	US 2004-996240	20041123
GB 2422837	A	20060809	GB 2006-10482	20041123
DE 112004002318	T5	20070118	DE 2004-112004002318	20041123
JP 2007515954	T	20070621	JP 2006-541476	20041123
PRAI US 2003-525318P	P	20031126		
US 2004-542520P	P	20040206		
US 2004-544835P	P	20040213		
US 2004-547933P	P	20040226		
WO 2004-US39805	W	20041123		

AB The invention relates to transcriptional regulators and related methods thereof. Detg. genes from a subset of genes that are regulated by a transcriptional regulator is achieved by (a) selectively isolating chromatin from a cell; (b) selectively isolating chromatin fragments which

are bound by the transcriptional regulator; (3) amplifying both the bound chromatin fragments and isolated chromatin to generate amplified chromatin fragments and amplified control chromatin, resp.; (4) hybridizing the amplified control and the amplified fragments to a DNA microarray; and (5) detg. and comparing a hybridization signal at each of the spots on the microarray between those generated by the amplified control chromatin and the amplified chromatin fragments. The DNA microarray for detg. promoter occupancy in a human cell, comprises (1) at least 10,000 expt. spots, each comprising a promoter region from a human gene; and (2) at least 100 control spots, each control spot comprising a non-promoter region. Applicants selected 15,000 cDNAs from the NCBI RefSeq database, mapped them to NCBI Build 22 of the human genome using BLAST, and amplified sequences from the genomic region -750 bp to +250 bp relative to the transcriptional start site. The invention also identifies genes regulated/occupied by the transcription factors HNF-1.alpha., HNF-4.alpha., and HNF-6 in human hepatocytes and pancreatic islets. Thus, the invention relates to the identification of genes regulated by transcriptional regulators, to the treatment of diseases assocd. with abnormal function of a transcriptional regulator, and to the modulation of gene expression, including genes expressed in hepatocytes or pancreatic cells, through the modulation of transcriptional regulator activity.

L2 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1081026 CAPLUS
DN 142:50129
TI Microarray for determining expression of psychoneuroendocrinimmune genes and diagnosis of diseases
IN Nicholson, Ainsley; Vernon, Suzanne D.
PA The Government of the United States as Represented by the Secretary of the Department of Health and Human Services, USA
SO PCT Int. Appl., 254 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004108899	A2	20041216	WO 2004-US17686	20040604
WO 2004108899	A3	20070426		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

AU 2004245998 A1 20041216 AU 2004-245998 20040604
CA 2528162 A1 20041216 CA 2004-2528162 20040604
IN 2006DN00084 A 20070824 IN 2006-DN84 20060104
PRAI US 2003-475915P P 20030604
WO 2004-US17686 W 20040604

AB Disclosed are compns. and methods for microarrays comprising genes involved in psychoneuroendocrinimmune (PNI) activity. An oligonucleotide microarray composed entirely of PNI genes was designed, which can allow a researcher to assess the overall psychoneuroendocrineimmune state of an individual, and to observe systemic responses to various stresses. The PNI array has widespread applicability and marketability in the diagnosis and treatment of diseases that result from dysregulation of the hypothalamic-pituitary-adrenal axis. A total of 1451 genes encoding 1738 transcriptional products can be distinguished and samples from human or mouse can hybridize with equal affinity, facilitating animal studies. Arabidopsis and housekeeping genes are used as controls. To det. the extent of peripheral blood PNI gene expression, both EST and microarray databases were queried; there were 566 genes from an EST database that matched to one of 1622 genes in the PNI database. The utility of the PNI array is demonstrated for research of chronic fatigue syndrome and other diseases involving PNI.

L2 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:162713 CAPLUS
DN 140:198079
TI Vaccines comprising human tumor-associated antigen encoded by 1-8D interferon-induced gene for treating colon or prostate cancer
IN Eisenbach, Lea; Tirosh, Boaz; Carmon, Lior; Machlenkin, Arthur; Paz, Adrian; Tzehoval, Esther; Fridkin, Matityahu
PA Yeda Research and Development Co. Ltd., Israel; Mcinnis, Patricia
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004016643	A2	20040226	WO 2003-US23503	20030728
WO 2004016643	A3	20050630		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003256912 A1 20040303 AU 2003-256912 20030728
EP 1569514 A2 20050907 EP 2003-788282 20030728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006263342 A1 20061123 US 2005-524787 20050923
PRAI US 2002-403657P P 20020816
WO 2003-US23503 W 20030728
AB The invention relates to colon and prostate tumor assocd. antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor assocd. antigen peptides and to pharmaceutical compns., which are preferably anti-tumor vaccine compns., contg. a tumor assocd. antigen, at least one tumor assocd. antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compns. can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.

L2 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:60672 CAPLUS
DN 140:123717
TI Protein and nucleotide sequences of human and mouse Fragilis and Stella genes expressed in primordial germ cell and its therapeutic uses
IN Saitou, Mitinori; Surani, Azim
PA Cambridge University Technical Services Limited, UK
SO PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007723	A2	20040122	WO 2003-GB3093	20030717
WO 2004007723	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2493675 A1 20040122 CA 2003-2493675 20030717
AU 2003255720 A1 20040202 AU 2003-255720 20030717
EP 1521832 A2 20050413 EP 2003-764023 20030717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005532808 T 20051104 JP 2004-520898 20030717
US 2006035326 A1 20060216 US 2005-38676 20050118
PRAI GB 2002-16727 A 20020717
US 2002-397310P P 20020719
WO 2003-GB3093 W 20030717

AB We described two primordial germ cell-specifically expressed genes, Fragilis and Stella. The sequences and uses of human Stella and Fragilis are disclosed, as well as several related mouse sequences related to Fragilis. Stella and Fragilis which are markers for primordial germ cells and may be used to identify such cells in cell populations. They may also be used for diagnosing, treating and/or preventing diseases such as cancers.

L2 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:3065 CAPLUS
DN 140:72104
TI Method for diagnosis of colorectal tumors and pre-malignant lesions by the scoring of gene expression profiles, and antitumor drug screening using the same
IN Nakamura, Yusuke; Furukawa, Yoichi
PA Oncotherapy Science, Inc., Japan; Japan as Represented by the President of the University of Tokyo
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004001072	A2	20031231	WO 2002-JP12760	20021205
WO 2004001072	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2499709 A1 20031231 CA 2002-2499709 20021205
AU 2002349786 A1 20040106 AU 2002-349786 20021205
JP 2005529625 T 20051006 JP 2004-515468 20021205
US 2006199179 A1 20060907 US 2004-518938 20041217
PRAI US 2002-389994P P 20020619
WO 2002-JP12760 W 20021205

AB The invention provides objective methods for detecting and diagnosing colorectal cancers and pre-malignant lesions. For example, the methods disclosed herein can reliably detect very early-stage colorectal cancers. In one embodiment, the diagnostic method involves the scoring of gene expression profiles that discriminate between adenomas and carcinomas. The profile score calcd. acts as diagnostic indicator that can objectively indicate whether a sample tissue is non-cancerous, pre-cancerous, or cancerous. The present invention further provides methods of diagnosing colorectal tumors in a subject, methods of screening for therapeutic agents useful in the treatment of colorectal tumors, methods of treating colorectal tumors and method of vaccinating a subject against colorectal tumors.

L2 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:354356 CAPLUS
DN 135:120439
TI Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia
AU Kitahara, Osamu; Furukawa, Yoichi; Tanaka, Toshihiro; Kihara, Chikashi; Ono, Kenji; Yanagawa, Renpei; Nita, Marcelo E.; Takagi, Toshihisa; Nakamura, Yusuke; Tsunoda, Tatsuhiko
CS Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan
SO Cancer Research (2001), 61(9), 3544-3549
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB To identify a set of genes involved in the development of colorectal carcinogenesis, we compared expression profiles of colorectal

cancer cells from eight tumors with corresponding noncancerous colonic epithelia using a DNA microarray consisting of 9216 human genes. These cell populations had been rendered homogeneous by laser-capture microdissection. Expression change in more than half of the tumors was obsd. for 235 genes, i.e., 44 up-regulated and 191 down-regulated genes. The differentially expressed genes include those assocd. with signal transduction, metabolizing enzymes, prodn. of reactive oxygen species, cell cycle, transcription, mitosis, and apoptosis. Subsequent examn. of 10 genes (five up-regulated and five down-regulated) by semiquant. reverse transcription-PCR using the eight tumors together with an addnl. 12 samples substantiated the reliability of our anal. The extensive list of genes identified in these expts. provides a large body of potentially valuable information of colorectal carcinogenesis and represents a source of novel targets for cancer therapy.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT